Background and Purpose: Hyperintense vessels (HV) detected on fluid-attenuated inversion recovery (FLAIR) in patients with acute ischemic stroke (AIS) indicate cerebral hypoperfusion. However, the clinical meaning of changes in HV is yet to be clarified. Here, we investigated serial changes to HV in patients with AIS who received tissue plasminogen activator (t-PA) therapy. Methods: We studied t-PA patients presenting with HV on FLAIR in the middle cerebral artery territory. Patients underwent brain MRI 1 h before and after t-PA infusion. HV scores (range 1-7) were evaluated according to Alberta Stroke Program Early Computed Tomography Score territories, and then by subtracting HV scores at 1 h after t-PA infusion from those on admission, with a result of >1 defined as decrease in HV score (DHV). Patients were divided into 2 groups based on the presence or absence of DHV. Multivariate logistic regression analysis was conducted to identify variables independently associated with good outcome (modified Rankin Scale score at 90 days after stroke onset of 0-1). Results: A total of 118 consecutive patients were enrolled (73 men; mean age 76 ± 9.7; median initial National Institutes of Health Stroke Scale (NIHSS) 13; median initial HV score 5), of whom 52 (44%) had DHV. Patients with DHV showed a significantly lower NIHSS time course (p < 0.001) and significantly smaller infarct volume time course (p < 0.001) compared to those without DHV. Multivariate analysis showed that DHV was independently associated with good outcome (OR 3.89; 95% CI 1.55-9.77; p < 0.01). The sensitivity and specificity of DHV for good outcome were 70 and 68%, respectively. Conclusion: A DHV on FLAIR predicts good outcome in patients receiving t-PA.

Keywords:
Fluid-attenuated inversion recovery , Magnetic resonance imaging, Middle cerebral artery, Acute ischemic stroke, Tissue plasminogen activator, Stroke, Hyperintense vessels
1.
Yeo LL, Paliwal P, Teoh HL, Seet RC, Chan BP, Liang S, Venketasubramanian N, Rathakrishnan R, Ahmad A, Ng KW, Loh PK, Ong JJ, Wakerley BR, Chong VF, Bathla G, Sharma VK: Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol 2013;70:353-358.
2.
Rha JH, Saver JL: The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967-973.
3.
Hirano T, Yonehara T, Inatomi Y, Hashimoto Y, Uchino M: Presence of early ischemic changes on computed tomography depends on severity and the duration of hypoperfusion: a single photon emission-computed tomographic study. Stroke 2005;36:2601-2608.
4.
Yoshioka K, Ishibashi S, Shiraishi A, Yokota T, Mizusawa H: Distal hyperintense vessels on FLAIR images predict large-artery stenosis in patients with transient ischemic attack. Neuroradiology 2013;55:165-169.
5.
Haussen DC, Koch S, Saraf-Lavi E, Shang T, Dharmadhikari S, Yavagal DR: FLAIR distal hyperintense vessels as a marker of perfusion-diffusion mismatch in acute stroke. J Neuroimaging 2013;23:397-400.
6.
Pérez de la Ossa N, Hernández-Pérez M, Domènech S, Cuadras P, Massuet A, Millán M, Gomis M, López-Cancio E, Dorado L, Dávalos A: Hyperintensity of distal vessels on FLAIR is associated with slow progression of the infarction in acute ischemic stroke. Cerebrovasc Dis 2012;34:376-384.
7.
Huang X, Liu W, Zhu W, Ni G, Sun W, Ma M, Zhou Z, Wang Q, Xu G, Liu X: Distal hyperintense vessels on FLAIR: a prognostic indicator of acute ischemic stroke. Eur Neurol 2012;68:214-220.
8.
Hohenhaus M, Schmidt WU, Brunecker P, Xu C, Hotter B, Rozanski M, Fiebach JB, Jungehülsing GJ: FLAIR vascular hyperintensities in acute ICA and MCA infarction: a marker for mismatch and stroke severity? Cerebrovasc Dis 2012;34:63-69.
9.
Cheng B, Ebinger M, Kufner A, Köhrmann M, Wu O, Kang DW, Liebeskind D, Tourdias T, Singer OC, Christensen S, Warach S, Luby M, Fiebach JB, Fiehler J, Gerloff C, Thomalla G: Hyperintense vessels on acute stroke fluid-attenuated inversion recovery imaging: associations with clinical and other MRI findings. Stroke 2012;43:2957-2961.
10.
Azizyan A, Sanossian N, Mogensen MA, Liebeskind DS: Fluid-attenuated inversion recovery vascular hyperintensities: an important imaging marker for cerebrovascular disease. AJNR Am J Neuroradiol 2011;32:1771-1775.
11.
Sanossian N, Saver JL, Alger JR, Kim D, Duckwiler GR, Jahan R, Vinuela F, Ovbiagele B, Liebeskind DS: Angiography reveals that fluid-attenuated inversion recovery vascular hyperintensities are due to slow flow, not thrombus. AJNR Am J Neuroradiol 2009;30:564-568.
12.
Lee KY, Latour LL, Luby M, Hsia AW, Merino JG, Warach S: Distal hyperintense vessels on FLAIR: an MRI marker for collateral circulation in acute stroke? Neurology 2009;72:1134-1139.
13.
Gawlitza M, Gragert J, Quäschling U, Hoffmann KT: FLAIR-hyperintense vessel sign, diffusion-perfusion mismatch and infarct growth in acute ischemic stroke without vascular recanalisation therapy. J Neuroradiol 2014;41:227-233.
14.
Toyoda K, Ida M, Fukuda K: Fluid-attenuated inversion recovery intraarterial signal: an early sign of hyperacute cerebral ischemia. AJNR Am J Neuroradiol 2001;22:1021-1029.
15.
Cosnard G, Duprez T, Grandin C, Smith AM, Munier T, Peeters A: Fast FLAIR sequence for detecting major vascular abnormalities during the hyperacute phase of stroke: a comparison with MR angiography. Neuroradiology 1999;41:342-346.
16.
Kono T, Naka H, Nomura E, Hosomi N, Aoki S, Imamura E, Sueda Y, Nezu T, Mukai T, Ohshita T, Ohtsuki T, Wakabayashi S, Matsumoto M: The association between hyperintense vessel sign and final ischemic lesion differ in its location. J Stroke Cerebrovasc Dis 2014;23:1337-1343.
17.
Ebinger M, Kufner A, Galinovic I, Brunecker P, Malzahn U, Nolte CH, Endres M, Fiebach JB: Fluid-attenuated inversion recovery images and stroke outcome after thrombolysis. Stroke 2012;43:539-542.
18.
Kamran S, Bates V, Bakshi R, Wright P, Kinkel W, Miletich R: Significance of hyperintense vessels on FLAIR MRI in acute stroke. Neurology 2000;55:265-269.
19.
Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke 2006;37:1810-1815.
20.
Kimura K, Sakamoto Y, Iguchi Y, Shibazaki K, Watanabe M, Aoki J, Inoue T, Uemura J: A simple clinical and MRI scale to predict good outcome in t-PA patients. Neurol Res 2011;33:1038-1043.
21.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
22.
Liu W, Xu G, Yue X, Wang X, Ma M, Zhang R, Wang H, Zhou C, Liu X: Hyperintense vessels on FLAIR: a useful non-invasive method for assessing intracerebral collaterals. Eur J Radiol 2011;80:786-791.
23.
Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med 1995;333:1581-1587.
24.
Liu W, Yin Q, Yao L, Zhu S, Xu G, Zhang R, Ke K, Liu X: Decreased hyperintense vessels on FLAIR images after endovascular recanalization of symptomatic internal carotid artery occlusion. Eur J Radiol 2012;81:1595-1600.
25.
Kawashima M, Noguchi T, Takase Y, Nakahara Y, Matsushima T: Decrease in leptomeningeal ivy sign on fluid-attenuated inversion recovery images after cerebral revascularization in patients with Moyamoya disease. AJNR Am J Neuroradiol 2010;31:1713-1718.
26.
Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T: Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan alteplase clinical trial II (J-ACT II). Stroke 2010;41:461-465.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.